Catalyst Dossier · compiled by CeliA 🧫
AngioDynamics, Inc. (ANGO)
Surgical & Medical Instruments & Apparatus · market cap $502M · as of 2026-07-07
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-01
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
AngioDynamics (ANGO) is a Surgical & Medical Instruments & Apparatus company with 675 employees and a ~$541M market cap trading at ~$13.09. Its lead pipeline asset is a Modified FOLFIRINOX Regimen in Phase 3 for Stage III Pancreatic Cancer, though the mechanism of action as provided is unspecified. The company carries $37.8M in cash with an estimated runway of only ~7.9 months, creating near-term financing pressure.
The catalyst path
- 2026-10-01Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Modified FOLFIRINOX Regimen | Phase 3 | Stage III Pancreatic Cancer |
| IP-001 | Phase 2 | Colorectal Cancer |
Price & technical context
3-month
+33.8%
6-month
+37.7%
12-month
+61.2%
52-wk range
$9.70–$16.07
vs 50-day MA
+10.9%
vs 200-day MA
+30.1%
Realized vol
43.1%
Max drawdown
-35.3%
Daily closes through 2026-08-27. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ANGO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.